{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:20:46Z","timestamp":1740122446397,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim GmbH","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The oral anticoagulant dabigatran offers an effective alternative to vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF), yet patient preference data are limited. The prospective observational RE-SONANCE study demonstrated that patients with AF, newly initiated on dabigatran, or switching to dabigatran from long-term VKA therapy, reported improved treatment convenience and satisfaction compared with VKA therapy. This pre-specified sub-study aimed to assess the impact of country and age on patients\u2019 perceptions of dabigatran or VKA therapy in AF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>RE-SONANCE was an observational, prospective, multi-national study (NCT02684981) that assessed treatment satisfaction and convenience in patients switching from VKAs to dabigatran (Cohort A), or newly diagnosed with AF receiving dabigatran or VKAs (Cohort B), using the PACT-Q questionnaire. Pre-specified exploratory outcomes: variation in PACT-Q2 scores by country and age (&lt;\u200965, 65 to &lt;\u200975, \u2265 75 years) (both cohorts); variation in PACT-Q1 responses at baseline by country and age (Cohort B).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients from 12 countries (Europe\/Israel) were enrolled in Cohort A (<jats:italic>n<\/jats:italic>\u2009=\u20094103) or B (<jats:italic>n<\/jats:italic>\u2009=\u20095369). In Cohort A, mean (standard deviation) PACT-Q2 score increase was highest in Romania (convenience: 29.6 [23.6]) and Hungary (satisfaction: 26.0 [21.4]) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In Cohort B, mean (standard error) increase in PACT-Q2 scores between dabigatran and VKAs was highest in Romania (visit 3: 29.0 [1.3]; 24.5 [0.9], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Mean PACT-Q2 score increase by age (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was similar across ages. PACT-Q1 responses revealed lowest expectations of treatment success in Romania and greatest concerns about payment in Estonia, Latvia, and Romania, but were similar across ages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment satisfaction and convenience tended to favor dabigatran over VKAs. Regional differences in treatment expectations exist across Europe.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial and clinical registry<\/jats:title>\n                <jats:p>Trial registration number: ClinicalTrials.gov NCT02684981.<\/jats:p>\n                <jats:p>Trial registration date: February 18, 2016.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11239-021-02450-2","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T14:04:58Z","timestamp":1619791498000},"page":"1195-1206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study"],"prefix":"10.1007","volume":"52","author":[{"given":"Dragos","family":"Vinereanu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Napalkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Benczur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Ciernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Gotcheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Medvedchikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pentti","family":"P\u00f5der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragan","family":"Simi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andris","family":"Skride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Trusz-Gluza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"issue":"38","key":"2450_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, ESC Scientific Document Group (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893\u20132962","journal-title":"Eur Heart J"},{"issue":"2","key":"2450_CR2","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW (2019) 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. Circulation 140(2):e125\u2013e151","journal-title":"Circulation"},{"issue":"21","key":"2450_CR3","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","volume":"115","author":"EM Hylek","year":"2007","unstructured":"Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689\u20132696","journal-title":"Circulation"},{"issue":"4","key":"2450_CR4","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/01.STR.0000208294.46968.a4","volume":"37","author":"E Birman-Deych","year":"2006","unstructured":"Birman-Deych E, Radford MJ, Nilasena DS, Gage BF (2006) Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 37(4):1070\u20131074","journal-title":"Stroke"},{"issue":"4","key":"2450_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/hrt.2004.042465","volume":"91","author":"M Jones","year":"2005","unstructured":"Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ (2005) Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 91(4):472\u2013477","journal-title":"Heart"},{"issue":"12","key":"2450_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee, Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"16","key":"2450_CR7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H, ESC Scientific Document Group (2018) The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330\u20131393","journal-title":"Eur Heart J"},{"issue":"3","key":"2450_CR8","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.ijcard.2013.03.059","volume":"168","author":"BU Monz","year":"2013","unstructured":"Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J (2013) Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 168(3):2540\u20132547","journal-title":"Int J Cardiol"},{"issue":"1","key":"2450_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40271-016-0185-9","volume":"10","author":"T Wilke","year":"2017","unstructured":"Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R (2017) Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review. Patient 10(1):17\u201337","journal-title":"Patient"},{"issue":"2","key":"2450_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.acvd.2017.04.007","volume":"111","author":"R De Caterina","year":"2018","unstructured":"De Caterina R, Bruggenjurgen B, Darius H, Kohler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P (2018) Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: a PREFER in AF Registry substudy. Arch Cardiovasc Dis 111(2):74\u201384","journal-title":"Arch Cardiovasc Dis"},{"key":"2450_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/PPA.S131158","volume":"12","author":"M Benzimra","year":"2018","unstructured":"Benzimra M, Bonnamour B, Duracinsky M, Lalanne C, Aubert JP, Chassany O, Aubin-Auger I, Mahe I (2018) Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence 12:79\u201387","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2450_CR12","doi-asserted-by":"publisher","first-page":"e001202","DOI":"10.1136\/openhrt-2019-001202","volume":"7","author":"D Vinereanu","year":"2020","unstructured":"Vinereanu D, Napalkov D, Bergler-Klein J, Benczur B, Ciernik M, Gotcheva N, Medvedchikov A, Poder P, Simic D, Skride A, Tang W, Trusz-Gluza M, Vesely J, Vishnepolsky T, Vrabec M (2020) Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study). Open Heart 7(1):e001202","journal-title":"Open Heart"},{"key":"2450_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1477-7525-7-30","volume":"7","author":"MH Prins","year":"2009","unstructured":"Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR (2009) Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes 7:30","journal-title":"Health Qual Life Outcomes"},{"key":"2450_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1477-7525-7-9","volume":"7","author":"MH Prins","year":"2009","unstructured":"Prins MH, Marrel A, Carita P, Anderson D, Bousser MG, Crijns H, Consoli S, Arnould B (2009) Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the \u2018Perception of Anticoagulant Treatment Questionnaire\u2019 (PACT-Q). Health Qual Life Outcomes 7:9","journal-title":"Health Qual Life Outcomes"},{"issue":"10104","key":"2450_CR15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(17)32165-7","volume":"390","author":"D Vinereanu","year":"2017","unstructured":"Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian Y, Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O, Tajer C, de Barros ESPGM, Roettig ML, Huo Y, Granger CB, IMPACT-AF investigators (2017) A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet 390(10104):1737\u20131746","journal-title":"Lancet"},{"issue":"1","key":"2450_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/europace\/euv317","volume":"18","author":"W Amara","year":"2016","unstructured":"Amara W, Larsen TB, Sciaraffia E, Hernandez Madrid A, Chen J, Estner H, Todd D, Bongiorni MG, Potpara TS, Dagres N, Sagnol P, Blomstrom-Lundqvist C (2016) Patients\u2019 attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace 18(1):151\u2013155","journal-title":"Europace"},{"issue":"3","key":"2450_CR17","doi-asserted-by":"publisher","first-page":"bjgpopen18X1016","DOI":"10.3399\/bjgpopen18X101602","volume":"2","author":"C Cimminiello","year":"2018","unstructured":"Cimminiello C, Hatala R, Pakarinen S, Friz HP, Fitzmaurice D, Hobbs FR (2018) Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey. BJGP Open 2(3):bjgpopen18X101602","journal-title":"BJGP Open"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02450-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-021-02450-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02450-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T08:03:31Z","timestamp":1637395411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-021-02450-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2450"],"URL":"https:\/\/doi.org\/10.1007\/s11239-021-02450-2","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"13 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dragos Vinereanu received grants and personal fees from Boehringer Ingelheim during the conduct of the study; grants and personal fees from Bristol-Myers Squibb, Pfizer, Bayer, Johnson & Johnson, and Daiichi Sankyo outside the submitted work. Dmitry Napalkov received research grants and has participated in scientific advisory boards for Boehringer Ingelheim and has received speaker\u2019s honoraria from Bayer, Boehringer Ingelheim, Pfizer, and Takeda. Bela Benczur received speaker\u2019s\/consultancy fees from Bayer, Berlin-Chemie\/Menarini, Boehringer Ingelheim, Krka Pharma, Novartis, Pfizer, Sandoz, and Sanofi. Martin Ciernik, Alexey Medvedchikov, and Wenbo Tang are employees of Boehringer Ingelheim. Pentti P\u00f5der received educational grants from Boehringer Ingelheim. Maria Trusz-Gluza received personal fees from Boehringer Ingelheim (null during the conduct of the study), personal fees and non-financial support from Boehringer Ingelheim, and personal fees from Bayer outside the submitted work. Ji\u0159\u00ed Vesely received personal fees and non-financial support from Bayer, Boehringer Ingelheim, Pfizer, MSD, and PRO.MED.CS outside the submitted work. All other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was carried out in accordance with the Declaration of Helsinki, International Conference of Harmonisation Tripartite Guideline, Good Clinical Practice, Guidelines for Good Epidemiological Practice and Good Pharmacoepidemiology Practice.  The study was initiated in centers once approved by the respective Institutional Review Board\/Independent Ethics Committee and competent authority, according to national and international regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from eligible patients prior to participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}